Zydus Cadila’s arm gets final approval to market Apremilast Tablets

24 Sep 2021 Evaluate

Zydus Cadila’s U.S. subsidiary -- Zydus Pharmaceuticals (USA) Inc has received final approval from the USFDA to market Apremilast Tablets in the strengths of 10 mg, 20 mg, 30 mg (US RLD: Otezla Tablets). Zydus’ Apremilast Tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.

The group now has 323 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.


Zydus Lifesciences Share Price

958.90 -0.55 (-0.06%)
23-Apr-2024 15:41 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1483.75
Dr. Reddys Lab 5947.30
Cipla 1347.70
Zydus Lifesciences 958.90
Lupin 1580.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.